Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Femasys Inc. - Common Stock (NQ:FEMY)

0.9313 -0.0185 (-1.95%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women-- 
From Femasys Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The Latest Analyst Ratings For Femasys
Via Benzinga
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
From Femasys Inc.
Via GlobeNewswire
The Analyst Verdict: Femasys In The Eyes Of 6 Experts
Via Benzinga
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
From Femasys Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday. 
Via Stocktwits
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
From Femasys Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
What's going on in today's after hours session
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
From Femasys Inc.
Via GlobeNewswire
Analyst Expectations For Femasys's Future
Via Benzinga
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million. 
Via Stocktwits
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option 
From Femasys Inc.
Via GlobeNewswire
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Assessing Femasys: Insights From 4 Financial Analysts
Via Benzinga
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
From Femasys Inc.
Via GlobeNewswire
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
First-in-world approval of FemBloc delivery system for women seeking permanent birth control 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
From Femasys Inc.
Via GlobeNewswire
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
UK regulatory approval follows FemaSeed, FemVue and FemCerv clearance/ approvals in the U.S., Europe, Canada and Israel 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Regulatory approval follows FemaSeed U.S. FDA-clearance announced September 2023 and EU CE mark approval announced June 2024 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
HRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across California 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients 
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.